Dublin, Ohio-based Cardinal Health is partnering with Magnolia Medical Technologies to reduce blood culture contamination and false-positive diagnoses for sepsis, according to a Nov. 14 news release.
Cardinal Health will implement Magnolia Medical Technologies' Steripath sepsis-diagnosing device to hospitals both as a standalone product and as part of a customizable device kit that aims to address blood culture contamination.
The Steripath device isolates the patient's blood portion that is most likely to contain contaminants and has presented up to 92 percent reduction in blood culture contamination, according to the news release.
With the device, Cardinal Health aims to decrease the impact of blood culture contamination on patient safety, quality outcome measures and healthcare costs.